BioWorld

Sep. 18, 2003

View Archived Issues

CytRx Raises $8.7M, Forms Subsidiary For RNAi Efforts

Raising $8.7 million in a private placement, CytRx Corp. said it's using most of the money to form a subsidiary that will develop orally active small-molecule RNA interference drugs for obesity and Type II diabetes. (BioWorld Today) Read More

Repligen, BMS Receive Patent Ruling; More Trouble Ahead?

Read More

South Koreans Reveal 3-D Structure Of Viagra Active Site - Drug Design With Better Pharmacological Profile

Read More

Aphton Raises $22.7M, Plans FDA Filing For Cancer Drug

Read More

ICAAC

Read More

Other News To Note

Read More